More than 80 U.S. lawmakers asked the FDA to stop counterfeit GLP-1 drugs linked to Chinese suppliers from entering the ...

India's anti-obesity drug market is valued at Rs 3,000-3,500 crore and is projected to grow nearly eightfold to Rs 25,000 ...

Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Hims & Hers Health, Inc. (NYSE: HIMS) and certain of the Company's senior executives for ...

Editors: Story has been updated from original, with material from the president of the Arizona Obesity Organization. Slug: ...

China's Sciwind Biosciences is in talks with a U.S. company interested in licensing its experimental weight-loss drug for ...

Dozens of lawmakers are urging US health regulators to crack down on the booming market for knockoff weight-loss drugs amid ...

Cipla is looking at the whole GLP-1 category and not just Semaglutide alone, says Cipla CEO Umang Vohra in a post-results ...

Ozempic and Mounjaro are both very popular for weight loss at the minute, but there's one big difference between the two ...

A spokesperson said: “Results from the STEP trials demonstrate that weight regain is likely once medication is stopped.

When glucagon-like peptide-1 receptor agonists (GLP-1s) like semaglutide (Wegovy) and liraglutide (Saxenda) were approved for ...